Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease

[1]  Jesper Jeppesen,et al.  Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study , 2018, Brain : a journal of neurology.

[2]  S. Houle,et al.  [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP , 2018, Brain Structure and Function.

[3]  Frank Jessen,et al.  In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults , 2017, NeuroImage.

[4]  Sergio Cerutti,et al.  Contrast mechanisms associated with neuromelanin‐MRI , 2017, Magnetic resonance in medicine.

[5]  Keith A. Johnson,et al.  Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case , 2017, Acta Neuropathologica Communications.

[6]  Duccio Volterrani,et al.  Neuroimaging in Parkinson's disease: focus on substantia nigra and nigro-striatal projection , 2017, Current opinion in neurology.

[7]  Tadeusz Sarna,et al.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease , 2017, Progress in Neurobiology.

[8]  S. Mallal,et al.  T cells of Parkinson’s disease patients recognize α–synuclein peptides , 2017, Nature.

[9]  Sander Nieuwenhuis,et al.  In vivo visualization of the locus coeruleus in humans: quantifying the test–retest reliability , 2017, Brain Structure and Function.

[10]  Dorothee P Auer,et al.  In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease: Potential as a Severity Marker for Multicenter Studies. , 2017, Radiology.

[11]  Daniel E. Huddleston,et al.  In vivo detection of lateral–ventral tier nigral degeneration in Parkinson's disease , 2017, Human brain mapping.

[12]  S. Fleming,et al.  Mechanisms of Gene-Environment Interactions in Parkinson’s Disease , 2017, Current Environmental Health Reports.

[13]  M. G. Bridelli,et al.  Synthesis, Structure Characterization, and Evaluation in Microglia Cultures of Neuromelanin Analogues Suitable for Modeling Parkinson's Disease. , 2017, ACS chemical neuroscience.

[14]  A. Abi-Dargham,et al.  194. Neuromelanin-sensitive Mri as an Early Indicator of Dopamine Dysfunction in Individuals at Risk for Psychosis , 2017 .

[15]  D. Surmeier,et al.  Calcium and Parkinson's disease. , 2017, Biochemical and biophysical research communications.

[16]  S. Aoki,et al.  Neuromelanin MRI is useful for monitoring motor complications in Parkinson’s and PARK2 disease , 2017, Journal of Neural Transmission.

[17]  Guangbin Wang,et al.  Subtypes evaluation of motor dysfunction in Parkinson’s disease using neuromelanin-sensitive magnetic resonance imaging , 2017, Neuroscience Letters.

[18]  Hanna Cho,et al.  Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[19]  Angelo Antonini,et al.  Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. , 2017, Journal of Parkinson's disease.

[20]  Comparison of Dopamine Transporter SPECT and 123I-MIBG Myocardial Scintigraphy to Assess Clinical Severity in Patients With Parkinson Disease , 2017, Clinical nuclear medicine.

[21]  Xiaoping Hu,et al.  Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI , 2017, Magnetic Resonance Materials in Physics, Biology and Medicine.

[22]  Masayuki Satoh,et al.  A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease , 2016, Neuroscience Letters.

[23]  W. Moon,et al.  A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging , 2016, Korean Journal of Radiology.

[24]  Luca Mainardi,et al.  Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease , 2016, Front. Aging Neurosci..

[25]  D. Brooks,et al.  In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. , 2016, Brain : a journal of neurology.

[26]  J. Audinot,et al.  Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano‐secondary ion mass spectrometry , 2016, Journal of neurochemistry.

[27]  E. Tolosa,et al.  Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility‐weighted imaging in idiopathic rapid eye movement sleep behavior disorder , 2016, Annals of neurology.

[28]  Ji Young Yun,et al.  Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With 123I‐FP‐CIT SPECT , 2016, Movement disorders : official journal of the Movement Disorder Society.

[29]  Andrew B Singleton,et al.  Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance , 2016, Journal of neurochemistry.

[30]  Marie Vidailhet,et al.  The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. , 2016, Brain : a journal of neurology.

[31]  Fumitoshi Kodaka,et al.  Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density , 2016, PloS one.

[32]  Xiaobo Wei,et al.  Position Emission Tomography/Single‐Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease , 2016, CNS neuroscience & therapeutics.

[33]  S. Fujii,et al.  Correlation between neuromelanin-sensitive MR imaging and 123I-FP-CIT SPECT in patients with parkinsonism , 2016, Neuroradiology.

[34]  N. Belluardo,et al.  Current disease modifying approaches to treat Parkinson’s disease , 2016, Cellular and Molecular Life Sciences.

[35]  K. Salikhov,et al.  Zavoisky and the discovery of EPR , 2015 .

[36]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[37]  Michael Schocke,et al.  Dorsolateral nigral hyperintensity on 3.0T susceptibility‐weighted imaging in neurodegenerative Parkinsonism , 2015, Movement disorders : official journal of the Movement Disorder Society.

[38]  R. Nunes,et al.  Substantia nigra neuromelanin‐MR imaging differentiates essential tremor from Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[39]  Carlos Ortiz-de-Solorzano,et al.  Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[40]  Xiangchuan Chen,et al.  A multicontrast approach for comprehensive imaging of substantia nigra , 2015, NeuroImage.

[41]  M. Tremblay,et al.  From the Cajal alumni Achúcarro and Río-Hortega to the rediscovery of never-resting microglia , 2015, Front. Neuroanat..

[42]  D. Sulzer,et al.  Neuroinflammation in Parkinson's disease animal models: a cell stress response or a step in neurodegeneration? , 2015, Current topics in behavioral neurosciences.

[43]  Xiaoping Hu,et al.  Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. , 2014, Magnetic resonance imaging.

[44]  Cyril Poupon,et al.  7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[45]  Jeff H Duyn,et al.  The role of iron in brain ageing and neurodegenerative disorders , 2014, The Lancet Neurology.

[46]  J. Volkmann,et al.  Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease , 2014, Front. Aging Neurosci..

[47]  Hisashi Tanaka,et al.  Neuromelanin Magnetic Resonance Imaging Reveals Increased Dopaminergic Neuron Activity in the Substantia Nigra of Patients with Schizophrenia , 2014, PloS one.

[48]  Yasuo Terayama,et al.  Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. , 2014, Parkinsonism & related disorders.

[49]  D. Sulzer,et al.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration , 2014, Nature Communications.

[50]  Agostinho Santos,et al.  ioinorganic chemistry ron levels in the human brain : A post-mortem study of anatomical egion differences and age-related changes , 2013 .

[51]  S. Fujii,et al.  Evaluation of Parkinson Disease and Alzheimer Disease with the Use of Neuromelanin MR Imaging and 123I-Metaiodobenzylguanidine Scintigraphy , 2013, American Journal of Neuroradiology.

[52]  Habib Benali,et al.  The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson’s disease , 2013, Brain : a journal of neurology.

[53]  Hidekazu Tomimoto,et al.  Neuromelanin Magnetic Resonance Imaging in Parkinson's Disease and Multiple System Atrophy , 2013, European Neurology.

[54]  D. Surmeier,et al.  Neuronal vulnerability, pathogenesis, and Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[55]  Shinya Fujii,et al.  Correlation between pathology and neuromelanin MR imaging in Parkinson’s disease and dementia with Lewy bodies , 2013, Neuroradiology.

[56]  Yasuo Terayama,et al.  Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging , 2013, Neuroscience Letters.

[57]  D. Sulzer,et al.  Neuromelanin of the Human Substantia Nigra: An Update , 2013, Neurotoxicity Research.

[58]  K. Wakamatsu,et al.  Neuromelanins of Human Brain Have Soluble and Insoluble Components with Dolichols Attached to the Melanic Structure , 2012, PloS one.

[59]  M. Esiri,et al.  Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's Cognitive Function and Ageing Study. , 2012, Metallomics : integrated biometal science.

[60]  K. Laere,et al.  European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  P. Crenna,et al.  Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease , 2011, BMC neurology.

[62]  F. Cupaioli,et al.  Chapter 9:The Role of Iron in Neurodegeneration , 2011 .

[63]  真司 田中,et al.  3テスラMRIによる中脳黒質neuromelanin-related contrastの描出:正常およびパーキンソン病における比較 , 2011 .

[64]  Makoto Tanaka,et al.  [Neuromelanin-related contrast in the substantia nigra semiquantitatively evaluated by magnetic resonance imaging at 3T: comparison between normal aging and Parkinson disease]. , 2011, Rinsho shinkeigaku = Clinical neurology.

[65]  K. Kashihara,et al.  Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. , 2011, Internal medicine.

[66]  Stanley Fahn,et al.  Neurodegeneration and neuroprotection in Parkinson disease , 2011, NeuroRX.

[67]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[68]  K P Bhatia,et al.  The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[69]  G. Cohen.  Iron-Sulfur Proteins , 2010 .

[70]  J. Bulte,et al.  Direct saturation MRI: Theory and application to imaging brain iron , 2009, Magnetic resonance in medicine.

[71]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[72]  D. Sulzer,et al.  Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.

[73]  G. Edwards,et al.  Neuromelanins Isolated from Different Regions of the Human Brain Exhibit a Common Surface Photoionization Threshold , 2009, Photochemistry and photobiology.

[74]  D. Sulzer,et al.  Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease , 2009, Neurotoxicity Research.

[75]  N. Turro,et al.  New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals , 2008, Proceedings of the National Academy of Sciences.

[76]  Alberto Albertini,et al.  Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease , 2008, Journal of neurochemistry.

[77]  D. Sulzer,et al.  Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease , 2008, Journal of neurochemistry.

[78]  P. Riederer,et al.  Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. , 2007, Journal of neural transmission. Supplementum.

[79]  Eri Shibata,et al.  Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. , 2006, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[80]  G. Edwards,et al.  The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface , 2006, Proceedings of the National Academy of Sciences.

[81]  A. Antonini,et al.  Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation , 2006, Movement disorders : official journal of the Movement Disorder Society.

[82]  Yasuo Terayama,et al.  Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease , 2006, Neuroreport.

[83]  L. Zecca,et al.  Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability , 2006, Journal of Neural Transmission.

[84]  P. Riederer,et al.  Dolichol is the major lipid component of human substantia nigra neuromelanin , 2005, Journal of neurochemistry.

[85]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[86]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[87]  Alberto Gatti,et al.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[88]  D. German,et al.  Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter‐2: Human midbrain dopamine neurons , 2004, The Journal of comparative neurology.

[89]  P. Riederer,et al.  Iron-binding characteristics of neuromelanin of the human substantia nigra. , 2003, Biochemical pharmacology.

[90]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[91]  G. Barker,et al.  Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. , 2002, Magnetic resonance imaging.

[92]  B. Pakkenberg,et al.  Ageing of substantia nigra in humans: 
cell loss may be compensated by hypertrophy , 2002, Neuropathology and applied neurobiology.

[93]  B. Bergamasco,et al.  Magnetic investigations of human mesencephalic neuromelanin. , 2002, Biochimica et biophysica acta.

[94]  Alberto Gatti,et al.  The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.

[95]  D. Sulzer,et al.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.

[96]  M. Gallorini.  Combined biochemical separation and INAA for the determination of iron and other metals in Neuromelanin of human brain Substantia Nigra , 2001, Journal of Radioanalytical and Nuclear Chemistry.

[97]  L. Zecca,et al.  The determination of iron and other metals by INAA in Cortex, Cerebellum and Putamen of human brain and in their neuromelanins , 2001 .

[98]  M Gallorini,et al.  Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes , 2001, Journal of neurochemistry.

[99]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[100]  J. Haycock,et al.  Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size , 2000, The Journal of Neuroscience.

[101]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[102]  S. Ito,et al.  Interaction of Human Substantia Nigra Neuromelanin with Lipids and Peptides , 2000, Journal of neurochemistry.

[103]  B. Bergamasco,et al.  Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. , 2000, Biochimica et biophysica acta.

[104]  Y. Agid,et al.  Preservation of midbrain catecholaminergic neurons in very old human subjects. , 2000, Brain : a journal of neurology.

[105]  Ma,et al.  Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing , 1999, Neuropathology and applied neurobiology.

[106]  L. Zecca,et al.  X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues. , 1998, Biophysical journal.

[107]  S. Ito,et al.  Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? , 1998, Neuroscience Letters.

[108]  J. Meldolesi,et al.  High-resolution calcium mapping of the endoplasmic reticulum-Golgi-exocytic membrane system. Electron energy loss imaging analysis of quick frozen-freeze dried PC12 cells. , 1997, Molecular Biology of the Cell.

[109]  R Weissleder,et al.  Paramagnetic metal scavenging by melanin: MR imaging. , 1997, Radiology.

[110]  B. Bergamasco,et al.  EPR investigations of the iron domain in neuromelanin. , 1997, Biochimica et biophysica acta.

[111]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[112]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[113]  T. Shima,et al.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.

[114]  H. M. Swartz,et al.  Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.

[115]  M. Barcikowska,et al.  Iron in parkinsonian and control substantia nigra—A mössbauer spectroscopy study , 1996, Movement disorders : official journal of the Movement Disorder Society.

[116]  R. Bryant,et al.  The dynamics of water-protein interactions. , 1996, Annual review of biophysics and biomolecular structure.

[117]  C G Peterfy,et al.  MR imaging. , 1996, Bailliere's clinical rheumatology.

[118]  C. Palivan,et al.  CHARACTERIZATION BY ELECTRON PARAMAGNETIC RESONANCE SPECTROSCOPY OF THE COORDINATION ENVIRONMENT OF COPPER IN SOME COPPER(II) COMPLEXES OF ASYMMETRIC TRIAZINES HAVING HIGH SUPEROXIDE DISMUTASE ACTIVITY , 1995 .

[119]  P. Riederer,et al.  Mössbauer Spectroscopic Studies of Purified Human Neuromelanin Isolated from the Substantia Nigra , 1995, Journal of neurochemistry.

[120]  J. Markley,et al.  NMR spectroscopic studies of paramagnetic proteins: iron-sulfur proteins. , 1995, Annual review of biophysics and biomolecular structure.

[121]  C. Morris,et al.  Iron histochemistry of the substantia nigra in Parkinson's disease. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[122]  D. Radice,et al.  Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.

[123]  W. S. Enochs,et al.  Purified Human Neuromelanin, Synthetic Dopamine Melanin as a Potential Model Pigment, and the Normal Human Substantia Nigra: Characterization by Electron Paramagnetic Resonance Spectroscopy , 1993, Journal of neurochemistry.

[124]  H. M. Swartz,et al.  Total and paramagnetic metals in human substantia nigra and its neuromelanin , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[125]  D B Hinshaw,et al.  Effects of the interaction between ferric iron and L‐dopa melanin on T1 and T2 relaxation times determined by magnetic resonance imaging , 1992, Magnetic resonance in medicine.

[126]  E. Parati,et al.  The chemical characterization of melanin contained in substantia nigra of human brain. , 1992, Biochimica et biophysica acta.

[127]  M. Lipton,et al.  Synergistic enhancement of MRI with Gd-DTPA and magnetization transfer. , 1992, Journal of computer assisted tomography.

[128]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[129]  W. Gibb,et al.  Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[130]  J. Connor,et al.  Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains , 1990, Journal of neuroscience research.

[131]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[132]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[133]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[134]  K. Johnson.  An Update. , 1984, Journal of food protection.

[135]  J. Dankert,et al.  PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.

[136]  G. Fenichel,et al.  Studies on neuromelanin: II. Melanin in the brainstems of infants and children , 1968, Neurology.

[137]  O. Hornykiewicz,et al.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. , 1998, Klinische Wochenschrift.

[138]  L. Griffiths.  Detection and Identification of the Polyphenoloxidase Substrate of the Banana , 1959, Nature.

[139]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[140]  I. Rabi,et al.  A New Method of Measuring Nuclear Magnetic Moment , 1938 .

[141]  P. James.  An Essay on the Shaking Palsy , 1817, The Medico-Chirurgical Journal and Review.